Skip to content

Efficacy of Rasasindura in the management of Type 2 Diabetes mellitus

clinical efficacy of dwiguna balijarita antardhooma talastha rasasindura along with guduchi ghana in the managment of madhumeha(type 2 diabetes)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044790
Enrollment
30
Registered
2022-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

ITRA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Both the sexes having age between 30 to 60 years Patients having a one among chief complaints of Madhumeha (Prabhuta-Avilamutrata, Pipasadhikya, Kshudhadhikya etc.) Known patient of Type 2 diabetes and also the preliminarily diagnosed patients on the basis of signs and symptoms of the disease are confirmed by FBS and PPBS Patients having Fasting blood sugar level �126 mg/dl and or PPBS level �200 mg/dl Patients on conventional (Allopathic) oral hypoglyemic agents with and without medications for management of diabetes unchanged over period of last 3 months

Exclusion criteria

Exclusion criteria: Age more than 60 and below 30 years Prameha Pidaka (Diabetic non healing wound), systemic infection, active infection other than superficial mild skin infestation Secondary diabetes mellitus. Patients of any other severe illness. Type 1 diabetes Malignant and accelerated hypertensive. Other chronic debilitating diseases. Pregnant woman and expecting conception (within six month) Lactating mothers. Patients with fatal diabetic complication like end stage renal disease Patient with diabetic ketoacidosis, diabetic nephropathy (end stage renal disease). Patients on Insulin and are dire need of it.

Design outcomes

Primary

MeasureTime frame
Improvement on cardinal signs and symptoms after treatment and at the end of follow up.Timepoint: 90 days

Secondary

MeasureTime frame
Improvement in biochemical parameters of bloodTimepoint: 1st to 90days

Countries

India

Contacts

Public ContactProfB J Patgiri

ITRA Jamnagar.

drprashantbedarkar@gmail.com8128217370

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026